About: 1. From molecular pathways to clinical trials

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : 1. From molecular pathways to clinical trials Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	Concept
rdfs:label	1. From molecular pathways to clinical trials
skos:inScheme	http://hub.abes.fr/referentiel/bmjarticlecategories
is Subject of	Efficacy of TNF switch after failure of one TNF inhibitor - results from a nation-wide observational study Expression of IL-20 in lesional skin and synovium of patients with psoriatic arthritis compared to rheumatoid arthritis and its response to ALEFACEPT treatment Systems biology of SLE: biochemical characterisation of subgroups within sle for improved diagnosis and treatment CTLA-4-IG (ABATACEPT) therapy reduces t cell function for all defined cd4 cell subsets including regulatory T cells (TREG) Long-term effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow-cytometry for more sensitive assessment of B cell depletion Expression levels of interleukin-17a, interleukin-17f and their receptors in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: a target validation study Safe and efficient transduction of synovial tissue after local injection of AAV5.hIFNβ in non-human primates with collagen-induced arthritis Monocytes transcriptom from sle and ra patients revelaed the disease-specific imprint of TNFα, IFNα and IFNγ Abatacept (CTLA-4Ig) therapy prevents activation induced cell death (AICD) of regulatory T cells and reduces the susceptibility of T cells to regulatory T cell suppression in patients with rheumatoid arthritis (RA) IL-35 gene therapy in a model of rheumatoid arthritis Cytokines in lupus nephritis, levels of IL-17 and IL-23 in association to histopathology and response to treatment The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNFα on endothelial cells A proposed mechanism for autonomic dysfunction in rheumatoid arthritis - reduced vagal activity related to high intrathecal IL-1β levels 1,25(OH)2D3 modulates gene expression involved in cytokine production, proliferation, survival and migration of TH17 cells from patients with rheumatoid arthritis Immunosuppressive DX5+ T cells are potent inhibitors of Th-1 responses via modulation of DCs Biologics use in sle in 23 centers - data from the international registry for biologics in SLE Targeting therapeutics to arthritic joints by antibody specific to post-translationally modified collagen type II Polymyalgia rheumatica is characterised by pro-inflammatory, late stage CD8+ T cells The transcriptomic analysis from pbmc is a powerful approach to identify specific signatures able to predict responses for each tnfalpha blocking agent The COX/prostaglandin-E2 pathway is critical for autocrine IL-17A production by TH17 cells upon synovial fibroblast interaction SLE immune complexes upregulate the expression of slamf7 (cd319) on plasmacytoid dendritic cells Modulation of IL-17 producing cells in estrogen-mediated inhibition of experimental arthritis Increased innate immune responses by interleukin-22 contributes to the inflammatory process in rheumatoid arthritis Evaluation of the danger signal HMGB1 as a potential biomarker in juvenile idiopathic arthritis (JIA): a preliminary study using the novel biobank jabba Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying antirheumatic drugs LL-37 is expressed in the inflamed synovium in patients with rheumatoid arthritis and downregulated by TNF inhibitors CD3ζ-chain expression is regulated by tumor necrosis factor via Src-like adaptor protein dependent proteosomal degradation in human T lymphocytes Toll-like receptor triggering can synergise with ige-mediated activation in ACPA+RA IgG glycan hydrolysis by EndoS diminishes the pro-inflammatory properties of immune complexes from patients with SLE - a possible new treatment? Does ACR/EULAR remission mean improved functional ability, quality of life and work productivity? Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis Anti-IL6R treatment acts on CD4+ FoxP3+ regulatory T cells in a model of rheumatoid arthritis Decreased interleukin-6 receptor (IL-6Rα) and increased signal transducer and activator of transcription 3 (Stat3) phosphorylation in rheumatoid arthritis (RA) are reversed by IL-6Rα blockade Refractory SLE patients respond to the proteasome inhibitor bortezomib Novel regulation of TNFα-induced-IL-18 bioactivity in rheumatoid arthritis synovial fibroblasts by reducing caspase-1 Via JAK2 inhibition Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration Frequency and route of administration in the treatment of experimental arthritis by phosphorus-based dendrimer Targeting autoreactive plasma cells in autoimmunity: a new treatment approach combining plasma cell and B cell depletion

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata